Sigma Investment Counselors Inc. Purchases 59 Shares of Eli Lilly and Company (NYSE:LLY)

Sigma Investment Counselors Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 2.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,150 shares of the company’s stock after purchasing an additional 59 shares during the quarter. Sigma Investment Counselors Inc.’s holdings in Eli Lilly and were worth $697,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. Norges Bank bought a new stake in Eli Lilly and during the fourth quarter worth about $2,213,765,000. Capital World Investors raised its stake in Eli Lilly and by 17.0% during the first quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock worth $6,402,838,000 after acquiring an additional 3,242,548 shares in the last quarter. Capital International Investors raised its stake in Eli Lilly and by 30.5% during the first quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock worth $2,532,024,000 after acquiring an additional 2,063,557 shares in the last quarter. 1832 Asset Management L.P. raised its stake in Eli Lilly and by 2,999.1% during the first quarter. 1832 Asset Management L.P. now owns 1,621,696 shares of the company’s stock worth $458,118,000 after acquiring an additional 1,569,368 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in Eli Lilly and by 38.5% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,525,748 shares of the company’s stock worth $1,254,743,000 after acquiring an additional 1,257,817 shares in the last quarter. Institutional investors own 82.45% of the company’s stock.

Eli Lilly and Stock Up 0.1 %

LLY traded up $0.39 during midday trading on Friday, hitting $311.26. The company had a trading volume of 134,176 shares, compared to its average volume of 2,237,822. Eli Lilly and Company has a 52 week low of $220.20 and a 52 week high of $335.33. The company has a quick ratio of 0.85, a current ratio of 1.10 and a debt-to-equity ratio of 1.70. The company has a market capitalization of $295.75 billion, a price-to-earnings ratio of 49.58, a PEG ratio of 1.92 and a beta of 0.38. The stock’s 50 day moving average price is $314.33 and its 200 day moving average price is $304.45.

Eli Lilly and (NYSE:LLYGet Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). The company had revenue of $6.49 billion during the quarter, compared to the consensus estimate of $6.85 billion. Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period last year, the firm posted $1.87 earnings per share. On average, research analysts anticipate that Eli Lilly and Company will post 7.97 earnings per share for the current fiscal year.

Eli Lilly and Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 9th. Shareholders of record on Monday, August 15th were given a dividend of $0.98 per share. The ex-dividend date was Friday, August 12th. This represents a $3.92 annualized dividend and a dividend yield of 1.26%. Eli Lilly and’s dividend payout ratio is currently 62.52%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. JPMorgan Chase & Co. boosted their target price on Eli Lilly and from $340.00 to $355.00 in a research note on Wednesday, June 1st. Citigroup boosted their target price on Eli Lilly and from $285.00 to $370.00 in a research note on Thursday, August 25th. Barclays raised their price objective on shares of Eli Lilly and from $333.00 to $355.00 and gave the company an “overweight” rating in a report on Thursday, July 7th. Morgan Stanley boosted their target price on shares of Eli Lilly and from $395.00 to $412.00 and gave the stock an “overweight” rating in a report on Wednesday, September 7th. Finally, UBS Group upgraded shares of Eli Lilly and from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $335.00 to $363.00 in a report on Thursday. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $332.19.

Insider Activity

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 41,857 shares of the company’s stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $329.05, for a total transaction of $13,773,045.85. Following the transaction, the insider now owns 104,161,953 shares in the company, valued at approximately $34,274,490,634.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, major shareholder Lilly Endowment Inc sold 41,857 shares of the firm’s stock in a transaction on Monday, June 27th. The shares were sold at an average price of $329.05, for a total transaction of $13,773,045.85. Following the completion of the transaction, the insider now directly owns 104,161,953 shares of the company’s stock, valued at $34,274,490,634.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jackson P. Tai purchased 656 shares of the stock in a transaction dated Friday, August 12th. The stock was acquired at an average cost of $304.19 per share, with a total value of $199,548.64. Following the transaction, the director now directly owns 62,857 shares in the company, valued at approximately $19,120,470.83. The disclosure for this purchase can be found here. Over the last three months, insiders sold 328,125 shares of company stock worth $108,581,151. 0.12% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.